The Latest Breaking News from Catalyst Pharmaceuticals

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga · Jun 26, 2025

Catalyst Pharmaceuticals (CPRX) vs. Johnson & Johnson (JNJ): Predicting the Dominant Pharma Stock in 2024

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….

StockNews.com · Dec 22, 2023

September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

StockNews.com · Sep 8, 2023

Catalyst Pharmaceuticals's Return On Capital Employed Insights

According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to $38.31 million.

Benzinga · Mar 17, 2022

Recap: Catalyst Pharmaceuticals Q4 Earnings

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · Mar 16, 2022

Earnings Preview For Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate that Catalyst Pharmaceuticals will report an earnings per share (EPS) of $0.12.

Benzinga · Mar 15, 2022

Catalyst Pharmaceuticals: A Biotech Stock Worth Owning

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) has been advancing with the help of its product, FIRDAPSE. Furthermore, its top and bottom line grew in its last reported quarter. So, let’s discuss in detail why it could be wise to add CPRX to one’s portfolio now. Read on.

StockNews.com · Jan 18, 2022